Zymeworks Price to Free Cash Flow Ratio 2016-2022 | ZYME
Historical price to free cash flow ratio values for Zymeworks (ZYME) since 2016.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Zymeworks Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-01-26 |
9.75 |
|
0.00 |
| 2022-06-30 |
5.30 |
$-3.87 |
0.00 |
| 2022-03-31 |
6.55 |
$-4.09 |
0.00 |
| 2021-12-31 |
16.39 |
$-3.93 |
0.00 |
| 2021-09-30 |
29.04 |
$-3.86 |
0.00 |
| 2021-06-30 |
34.69 |
$-3.15 |
0.00 |
| 2021-03-31 |
31.58 |
$-3.12 |
0.00 |
| 2020-12-31 |
47.26 |
$-3.09 |
0.00 |
| 2020-09-30 |
46.58 |
$-3.27 |
0.00 |
| 2020-06-30 |
36.07 |
$-2.99 |
0.00 |
| 2020-03-31 |
35.47 |
$-2.43 |
0.00 |
| 2019-12-31 |
45.46 |
$-2.32 |
0.00 |
| 2019-09-30 |
24.80 |
$0.49 |
50.79 |
| 2019-06-30 |
22.00 |
$0.21 |
104.17 |
| 2019-03-31 |
16.18 |
$0.83 |
19.45 |
| 2018-12-31 |
14.68 |
$0.80 |
18.27 |
| 2018-09-30 |
15.70 |
$0.42 |
37.28 |
| 2018-06-30 |
14.78 |
$1.01 |
14.69 |
| 2018-03-31 |
12.02 |
$-0.78 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.616B |
$0.027B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
